United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - exemestane - oral tablet - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - exemestane - oral tablet - 25mg

Ireland - English - HPRA (Health Products Regulatory Authority)

helm pharmaceuticals gmbh - exemestane - coated tablets - 25 milligram

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - exemestane - tablet, sugar coated - 25 mg - exemestane 25 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - exemestane - coated tablets - 25 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - exemestane -

Canada - English - Health Canada

pfizer canada ulc - exemestane - tablet - 25mg - exemestane 25mg - antineoplastic agents

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - exemestane - coated tablet - exemestane 25 mg - endocrine therapy

Ireland - English - HPRA (Health Products Regulatory Authority)

originalis b.v. - exemestane - coated tablet - 25 milligram(s) - exemestane

Israel - English - Ministry of Health

vitamed pharmaceutical industries ltd - exemestane - film coated tablets - exemestane 25 mg - exemestane - exemasin-vit is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone.exemasin-vit is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. exemasin-vit is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.